GREM2 and PIK3C2G as senescence-associated genes in esophageal squamous cell carcinoma
In an abstract-level analysis, GREM2 and PIK3C2G were downregulated in esophageal squamous cell carcinoma tumors and cell lines, and low expression predicted poorer overall survival; cell experiments linked both genes to senescence and reduced proliferation. [1]
Automatic summary · not editorially reviewed
The key findings
The researchers combined TCGA-ESCC transcriptomic profiles with a curated panel of senescence-related genes and split patients into two molecular subtypes with divergent survival. [1]
GREM2 and PIK3C2G were consistently downregulated in ESCC tumors and cell lines, and low expression predicted poorer overall survival. [1]
Immune correlation analyses linked both genes to immune cell infiltration, chemokine signaling and MHC molecule expression in the tumor microenvironment. [1]
The source at a glance
- Study type / format
- Abstract of a bioinformatic and experimental laboratory study
- Population / context
- Patients with esophageal squamous cell carcinoma (TCGA-ESCC and GSE20347 cohorts) and esophageal epithelial cell lines
- Summary based on
- Study abstract
- Original publication
- October 15, 2026
TCGA-ESCC subtypes and survival in the abstract
The abstract describes esophageal squamous cell carcinoma (ESCC) as an aggressive cancer with poor clinical outcomes and says how cellular senescence affects ESCC biology is poorly understood. The researchers combined transcriptomic profiles from the TCGA-ESCC cohort with a curated panel of senescence-related genes. Using univariate Cox regression and consensus clustering, they sorted ESCC patients into two molecular subtypes with divergent survival. The abstract does not report cohort size, follow-up length or the size of the gene panel.
Supporting source [1]
GREM2 and PIK3C2G downregulated in ESCC tumors
Through differential expression analysis, random forest prioritization and independent validation in the GSE20347 cohort, the authors identified GREM2 and PIK3C2G as lead candidate genes. Both were consistently downregulated in ESCC tumors and cell lines, and low expression predicted poorer overall survival. Gain- and loss-of-function experiments indicated that GREM2 and PIK3C2G drive p16/p21-dependent cellular senescence, trigger the senescence-associated secretory phenotype (SASP) and restrict proliferation in esophageal epithelial cells. These are experimental and association findings, not proof that the genes cause or prevent cancer in people.
Supporting source [1]
Immune links and biomarker claims in the abstract
Immune correlation analyses linked both genes to immune cell infiltration, chemokine signaling and MHC molecule expression in the tumor microenvironment. The authors conclude that GREM2 and PIK3C2G act as senescence-associated tumor suppressors in ESCC and present them as candidate biomarkers and a rationale for exploring senescence-directed therapies. The abstract does not report effect sizes, exact survival statistics or immune analysis details. Only the abstract was reviewed; the full text was not reviewed, so methods and results cannot be checked in detail.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Cohort size, follow-up, effect sizes and immune analysis details are not reported in the abstract. Findings are associations and cell experiments, not evidence of human lifespan or cancer-prevention benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhao W, Zhao S, Wang C, Dong G, Cui F, Wang M, Lin Z. · europepmc.org · October 15, 2026